The FDA last week granted a first-in-class nod to Gilead Sciences’ Yescarta for the treatment of large B-cell lymphoma that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy. Gilead eked out the victory ahead of Bristol Myers Squibb’s rival CAR-T drug Breyanzi for the same indication. Breyanzi’s review is set for this June. Yescarta was first approved for the treatment of large B-cell lymphoma that has not responded at least two other kinds of treatment in October 2017. For this indication, Yescarta holds covered or better status under the medical benefit for 78% of all insured lives.
SOURCE: MMIT Analytics, as of 4/4/22